Open Access Articles- Top Results for SB-742457


Systematic (IUPAC) name
Clinical data
  • Investigational
607742-69-8 7pxY
PubChem CID 11256720
ChemSpider 9431746 7pxN
ChEMBL CHEMBL1083390 7pxN
Chemical data
Formula C19H19N3O2S
353.44 g/mol
 14pxN (what is this?)  (verify)

SB-742457 (RVT-101[1]) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects.[2][3][4][5] It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials;[4][5][6] however, GSK chose not to continue development and sold the rights to Axovant.[7]


  1. ^ "RVT-101". Axovant. 
  2. ^ Upton N, Chuang TT, Hunter AJ, Virley DJ (July 2008). "5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease". Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics 5 (3): 458–69. PMID 18625457. doi:10.1016/j.nurt.2008.05.008. 
  3. ^ Idris N, Neill J, Grayson B et al. (January 2010). "Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms". Psychopharmacology 208 (1): 23–36. PMID 19851757. doi:10.1007/s00213-009-1702-5. 
  4. ^ a b Maher-Edwards G, Zvartau-Hind M, Hunter AJ et al. (December 2009). "Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease". Current Alzheimer Research 7 (5): 374–85. PMID 20043816. 
  5. ^ a b Rossé G, Schaffhauser H (February 2010). "5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment". Current Topics in Medicinal Chemistry 10 (2): 207–21. PMID 20166958. doi:10.2174/156802610790411036. 
  6. ^ "Search of: SB-742457 - List Results -". 
  7. ^ "Axovant Acquires SB742457 from GlaxoSmithKline". Axovant. December 23, 2014. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.